Medication info
Sitadual XR Sustained Release Tablet 50/1000 mg (Sitagliptin Hydrochloride Hydrate, Metformin Hydrochloride)

Sitadual XR Sustained Release Tablet 50/1000 mg (Sitagliptin Hydrochloride Hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
Bright green oval sustained-release film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300585 · Approved 2023.02.17 · Insurance code 642005000

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, swallow this medication whole; do not split, crush, grind, or chew it. The 100/1000 mg extended-release tablet of this medication is taken once daily, 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets of this medication take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of drug treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication. 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medication is sitagliptin 100 mg plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start with their current doses of sitagliptin and metformin. - Patients currently taking immediate-release metformin 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to improve blood sugar control by assisting dietary and exercise therapy in patients with Type 2 diabetes. By combining sitagliptin and metformin, it effectively lowers blood sugar and aids in diabetes management. Patients may expect better treatment outcomes by consistently taking the medication along with lifestyle improvements.

How to take

Adult dose

In antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, swallow this medication whole; do not split, crush, grind, or chew it. The 100/1000 mg extended-release tablet of this medication is taken once daily, 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets of this medication take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of drug treatment for diabetes whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication. 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medication is sitagliptin 100 mg plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start with their current doses of sitagliptin and metformin. - Patients currently taking immediate-release metformin 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains sitagliptin and metformin and is used to control blood sugar. First, severe allergic reactions may rarely occur during the usage of this medication, so if skin rash, difficulty breathing, or swelling of the face or lips occurs, you should stop taking the medication immediately and go to a hospital. Also, this medication may pose a risk of pancreatitis, an inflammation of the pancreas, so if abdominal pain, vomiting, or severe abdominal pain occurs, you need to inform medical personnel immediately. Due to the metformin component, a rare complication called lactic acidosis may occur, which could lead to a dangerous buildup of lactic acid in the body. Symptoms such as fatigue, muscle pain, difficulty breathing, and abdominal pain may present, necessitating caution. It is unsafe for patients with impaired kidney function, dehydration, severe infections, heart failure, acute myocardial infarction, or other certain conditions to take this medication. In particular, this medication should be temporarily stopped before and after undergoing tests using radioactive iodine contrast agents, and it should be restarted only after confirming that kidney function is normal. Women who are pregnant or may become pregnant, and those who are breastfeeding should not take this medication. Moreover, irregular meals or intense exercise, along with the use of certain medications, may increase the risk of hypoglycemia and lactic acidosis, so caution is required. This medication may cause side effects such as gastrointestinal disturbances, headaches, upper respiratory infections, and hypoglycemia; particularly, the risk of hypoglycemia may increase when taken with insulin or sulfonylureas. During treatment, it is necessary to regularly monitor kidney function and perform blood tests, as vitamin B12 levels may decrease, requiring supplementation if necessary. Alcohol can increase the risk of side effects from this medication, so excessive drinking should be avoided during treatment. If you are scheduled for surgery or in poor health due to severe infections or trauma, this medication should be temporarily stopped and resumed only after recovery. Finally, it is crucial to consult medical personnel immediately if any adverse symptoms occur while taking this medication.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 20 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis
  • increased liver enzymes
  • acute kidney failure
  • hypoglycemic episodes
  • peripheral edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container when in use. Additionally, it should be kept at room temperature between 1°C and 30°C, avoiding extreme heat or cold for safe use.

Appearance and packaging

Appearance

Bright green oval sustained-release film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.